Inhibikase Therapeutics, Inc.

IKT Healthcare Biotechnology

Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022. In the quarter to June 2026, EPS was flat and free cash flow fell 123.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

1.65 0.18 −9.84%
Market cap
$255.4M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
3/9
Altman Z
−8.82
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
11.73 21.70 30.14 15.82
Net Debt/EBITDA
6.07 12.98 9.55 7.55
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.12) (0.08) (0.07) (0.07)
Book value per Share
0.81 1.76 0.97 0.88
Free Cash Flow
(10.59) (7.52) (12.06) (12.44)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates